Literature DB >> 938018

Inactivation of gentamicin by penicillins in patients with renal failure.

F R Ervin, W E Bullock, C E Nuttall.   

Abstract

Kinetics of gentamicin inactivation by carbenicillin and ticarcillin were studied in vitro and in 17 patients with renal failure. In vitro, the half-life of carbenicillin in human serum at 37 C is longer (19.2 +/- 0.7 h) than ticarcillin (7.2 +/- 0.6 h). Thus, incubation of gentamicin with equal concentrations of ticarcillin or carbenicillin results in greater inactivation of aminoglycoside activity by the latter. If concentrations of the two penicillins are held equal by repetitive addition, rates of gentamicin inactivation are the same. The serum half-life of gentamicin in patients serving as their own controls was significantly reduced by administration of either penicillin. After carbenicillin, the half-life decreased from 46 +/- 8 h to 22 +/- 3 h (P < 0.02). The constant for inactivation of gentamicin (k(i)) by carbenicillin was 0.02 h(-1). The results indicate that gentamicin requirements are underestimated by methods currently employed to calculate dosage for patients with renal failure who receive carbenicillin concurrently. Adjustment of gentamicin dosage in such cases by application of the k(i) for gentamicin is suggested.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 938018      PMCID: PMC429665          DOI: 10.1128/AAC.9.6.1004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Drug distribution.

Authors:  S Feldman
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

2.  Individualization of drug dosage in patients with renal disease.

Authors:  L Dettli
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

3.  Gentamicin pharmacokinetics during hemodialysis.

Authors:  T G Christopher; D Korn; A D Blair; A W Forrey; M A O'Neill; R E Cutler
Journal:  Kidney Int       Date:  1974-07       Impact factor: 10.612

4.  Therapeutic implications of interaction of gentamicin and penicillins.

Authors:  P Noone; J R Pattison
Journal:  Lancet       Date:  1971-09-11       Impact factor: 79.321

5.  Pharmacology of gentamicin in man.

Authors:  L J Riff; G G Jackson
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Pharmacodynamics of carbenicillin in hepatic and renal failure.

Authors:  T A Hoffman; R Cestero; W E Bullock
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

7.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

8.  Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function.

Authors:  T W Wilson; W A Mahon; T Inaba; G E Johnson; D Kadar
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

9.  Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis.

Authors:  R Wise; D S Reeves; A S Parker
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

10.  Studies on the mechanism of the formation of the penicillin antigen. I. Delayed allergic cross-reactions among penicillin G and its degradation products.

Authors:  B B LEVINE
Journal:  J Exp Med       Date:  1960-12-01       Impact factor: 14.307

View more
  31 in total

1.  Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.

Authors:  G R Aronoff; R A Brier; R S Sloan; M E Brier
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

4.  Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease.

Authors:  M I Thompson; M E Russo; B J Saxon; E Atkin-Thor; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

6.  Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure.

Authors:  D C Blair; D O Duggan; E T Schroeder
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 7.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin.

Authors:  L A Bauer; R A Blouin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin.

Authors:  J N Walterspiel; S Feldman; R Van; W R Ravis
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.